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repaired, the p53-dependent apoptotic pathway is activated
9yelodysplastic syndromes (MDS) are a heterogeneous group
f clonal hematopoietic neoplasms, characterized by dysplas-
ic ﬁndings with variable degree of bone marrow failure and
roliferation of blast cells.1 It is the most common neoplastic
isease of the bone marrow, with an estimated incidence
f 1.3–5 per 100,000 people annually, and reaching 36 per
00,000 in patients aged 80 years or over. Risk factors include:
dvanced age (MDS de novo, corresponding to 90% of cases),
revious exposure to chemotherapy or radiation therapy
therapy-related MDS), aplastic anemia and constitutional
iseases, particularly those with abnormal DNA repair, such
s Fanconi anemia.2
The clinical course is highly variable with survival ranging
rom several years to a few months and variable risk of pro-
ression to acute myeloid leukemia (AML). Because of this
eterogeneity, the study of prognostic factors is very impor-
ant. Factors related to the individual (such as performance
tatus, co-morbidities, age and nutritional status), biological
severity of cytopenias, transfusion need, cytogenetic abnor-
alities, percentage of blasts, bone marrow ﬁbrosis, primary
r secondary disease) and social (access to health care and
edications) impact the survival. Themodelsmost commonly
sed in prognostic score for MDS de novo, such as the Interna-
ional Prognostic Scoring System (IPSS), the WHO Prognostic
coring System (WPSS), and the Revised International Progno-
tic Scoring System (IPSS-R) basically use biological variables,
btained from the study of blood cell counts (cytopenias), per-
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eserved.centage of blasts in bone marrow aspirate and cytogenetic
ﬁndings.3–5 Recently, cytogenetic ﬁndings were better deﬁned
and cytogenetic abnormalities were divided into 5 risk groups,
noting that the higher the complexity observed in the karyo-
type, the worst the survival is.5,6
Even in patients with normal karyotype, many genetic
mutations described by molecular biology techniques have
been associated with prognosis. For example, mutations in
TP53, EZH2, ETV6, RUNX1, and ASXL1 are predictors of poor
overall survival, independently of established risk factors.7,8
Although a better understanding of the physiopathology of
the disease is obtained with these studies, they are not rou-
tinely available. In this sense, the study of protein expression
altered by dysfunction of these genes, either by ﬂow cytometry
or by immunohistochemistry is cheaper and feasible in Brazil
and the study of p53 in bone marrow biopsy in MDS has been
quite interesting.
The p53 gene (located at 17p13) is a tumor suppressor gene
of great importance for genetic stability and integrity of the
genome. DNA damage of several types activates the 53kDa
nuclear phosphoprotein p53 protein, resulting in cell cycle
arrest at the G1 (post-mitotic phase) and G2 (pre-mitotic) cell
cycle checkpoints necessary for DNA repair. If the DNA is notic¸o de Hematologia Hospital das Clinicas FMUSP, Laboratório de
with cell death. Germline p53 mutations (Li–Fraumeni syn-
drome) are very rare, but acquired somatic p53 mutations are
often detected in solid tumors, leukemias and lymphomas.
e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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Figure 1 – Kaplan–Meier survival curve for secondary
myeloid neoplasia according to immunoexpression of p53
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The inactivation of the p53 gene in both alleles, loss of het-
erozygous (LOH), by mutations or deletions have been related
to the predisposition to neoplastic transformation. The wild
type gene product is a normal protein with a short half-life
of only 15min, while the p53 mutant proteins that form com-
plexes with heat shock protein 70 in the cytoplasm and bind
wild-type p53 have a longer half-life of several hours.10,11
Rearrangements resulting in loss of 17p (monosomy, deletion,
unbalanced translocations involving 17p or isochromosome
17q), usually as part of a complex karyotypes have been
observed in 5% of new cases of MDS.12
The p53 mutation is detected in about 5–20% of MDS de
novo,13–20 in 18% of patients with low-risk MDS and deletion
5q21 and in 25–70% in adult therapy-related MDS.8,22,23,24 The
p53 mutations are associated with complex karyotype with -
5/5q-, short survival, increased risk to transformation to AML
and poor response to therapy: patients with MDS de novo often
presentwith excess of blasts, andpatientswith the 5qdeletion
have less response to lenalidomide.
Immunohistochemistry and ﬂow cytometry are now
described as ideal methods for the detection of the p53 protein
in samples from leukemic patients. Although there is a general
correlation between the expression of p53 protein and muta-
tion, in some tumorswith nonsensemutations in their genetic
sequences (less than 20% of human tumors with p53 muta-
tion), the protein expression cannot be detected. On the other
hand, rare cases of positivep53 expressionwerenot associated
with the p53 mutation.11
Kitagawa detected the expression of p53 by immunohis-
tochemistry in 14% of patients with MDS, with half of them
having progressed to AML.11 Also, overexpression of this pro-
tein has been shown to be more common in patients in the
refractory anemia with excess blasts subgroup. In 22 cases
of secondary MDS studied in HCFMUSP, p53 immunoreactiv-
ity was observed in 33.3% and was associated in univariate
analysis with poor survival (Figure 1).24,25
The work published by Duarte et al. in this issue of the
Revista Brasileira de Hematologia e Hemoterapia validates the
value of p53 in bone marrow biopsies in low-risk MDS.26 Other
studies have also shown its prognostic value in higher risk and
12014;36(3):175–177
secondaryMDS.Due to the lowcost of immunohistochemistry,
reproducibility and availability in various centers of Brazil, we
suggest the routine study of p53 expression in bone marrow
biopsies of all MDS cases.
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